“Acute Graft-Versus-Host Disease Biomarkers Measured During Therapy Can Predict Treatment Outcomes: A Blood And Marrow Transplant Clinical Trials Network Study.”. Blood 119 (16). Blood: 3854-60. doi:10.1182/blood-2012-01-403063.
. 2012. “Allogeneic Hematopoietic Cell Transplant For Hiv Patients With Hematologic Malignancies: The Bmt Ctn-0903/amc-080 Trial.”. Biol Blood Marrow Transplant 25 (11). Biol Blood Marrow Transplant: 2160-2166. doi:10.1016/j.bbmt.2019.06.033.
. 2019. “Alternative Donor Transplantation After Reduced Intensity Conditioning: Results Of Parallel Phase 2 Trials Using Partially Hla-Mismatched Related Bone Marrow Or Unrelated Double Umbilical Cord Blood Grafts.”. Blood 118 (2). Blood: 282-8. doi:10.1182/blood-2011-03-344853.
. 2011. “Amphiregulin Modifies The Minnesota Acute Graft-Versus-Host Disease Risk Score: Results From Bmt Ctn 0302/0802.”. Blood Adv 2 (15). Blood Adv: 1882-1888. doi:10.1182/bloodadvances.2018017343.
. 2018. “Autologous Haemopoietic Stem-Cell Transplantation Followed By Allogeneic Or Autologous Haemopoietic Stem-Cell Transplantation In Patients With Multiple Myeloma (Bmt Ctn 0102): A Phase 3 Biological Assignment Trial.”. Lancet Oncol 12 (13). Lancet Oncol: 1195-203. doi:10.1016/S1470-2045(11)70243-1.
. 2011. “Comparison Of Patient-Reported Outcomes In 5-Year Survivors Who Received Bone Marrow Vs Peripheral Blood Unrelated Donor Transplantation: Long-Term Follow-Up Of A Randomized Clinical Trial.”. Jama Oncol 2 (12). Jama Oncol: 1583-1589. doi:10.1001/jamaoncol.2016.2520.
. 2016. “Exercise And Stress Management Training Prior To Hematopoietic Cell Transplantation: Blood And Marrow Transplant Clinical Trials Network (Bmt Ctn) 0902.”. Biol Blood Marrow Transplant 20 (10). Biol Blood Marrow Transplant: 1530-6. doi:10.1016/j.bbmt.2014.05.027.
. 2014. “Functional And Radiologic Assessment Of The Brain After Reduced-Intensity Unrelated Donor Transplantation For Severe Sickle Cell Disease: Blood And Marrow Transplant Clinical Trials Network Study 0601.”. Biol Blood Marrow Transplant 25 (5). Biol Blood Marrow Transplant: e174-e178. doi:10.1016/j.bbmt.2019.01.008.
. 2019. “Graft-Versus-Host Disease Treatment: Predictors Of Survival.”. Biol Blood Marrow Transplant 16 (12). Biol Blood Marrow Transplant: 1693-9. doi:10.1016/j.bbmt.2010.05.019.
. 2010. “Improved Survival After Transplantation Of More Donor Plasmacytoid Dendritic Or Naïve T Cells From Unrelated-Donor Marrow Grafts: Results From Bmtctn 0201.”. J Clin Oncol 32 (22). J Clin Oncol: 2365-72. doi:10.1200/JCO.2013.54.4577.
. 2014. “Infections After Transplantation Of Bone Marrow Or Peripheral Blood Stem Cells From Unrelated Donors.”. Biol Blood Marrow Transplant 22 (2). Biol Blood Marrow Transplant: 359-370. doi:10.1016/j.bbmt.2015.09.013.
. 2016. “Lymphocyte Phenotype During Therapy For Acute Graft-Versus-Host Disease: A Brief Report From Bmt-Ctn 0302.”. Biol Blood Marrow Transplant 19 (3). Biol Blood Marrow Transplant: 481-5. doi:10.1016/j.bbmt.2012.12.003.
. 2013. “Mismatched Related And Unrelated Donors For Allogeneic Hematopoietic Cell Transplantation For Adults With Hematologic Malignancies.”. Biol Blood Marrow Transplant 20 (10). Biol Blood Marrow Transplant: 1485-92. doi:10.1016/j.bbmt.2014.05.015.
. 2014. “Mycophenolate Pharmacokinetics And Association With Response To Acute Graft-Versus-Host Disease Treatment From The Blood And Marrow Transplant Clinical Trials Network.”. Biol Blood Marrow Transplant 16 (3). Biol Blood Marrow Transplant: 421-9. doi:10.1016/j.bbmt.2009.11.010.
. 2010. “Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation For Acute Myeloid Leukemia And Myelodysplastic Syndromes.”. J Clin Oncol 35 (11). J Clin Oncol: 1154-1161. doi:10.1200/JCO.2016.70.7091.
. 2017. “A Phase Ii/iii Randomized, Multicenter Trial Of Prednisone/sirolimus Prednisone/ Sirolimus/calcineurin Inhibitor For The Treatment Of Chronic Graft--Host Disease: Bmt Ctn 0801.”. Haematologica 103 (11). Haematologica: 1915-1924. doi:10.3324/haematol.2018.195123.
. 2018. “Plasma Biomarkers Of Risk For Death In A Multicenter Phase 3 Trial With Uniform Transplant Characteristics Post-Allogeneic Hct.”. Blood 129 (2). Blood: 162-170. doi:10.1182/blood-2016-08-735324.
. 2017. “Randomized, Double-Blind, Placebo-Controlled Trial Of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) For The Treatment Of Idiopathic Pneumonia Syndrome After Allogeneic Stem Cell Transplantation: Blood And Marrow Transplant Clinical Trials Ne”. Biol Blood Marrow Transplant 20 (6). Biol Blood Marrow Transplant: 858-64. doi:10.1016/j.bbmt.2014.02.026.
. 2014. “Reduced-Intensity Conditioning With Fludarabine, Cyclophosphamide, And High-Dose Rituximab For Allogeneic Hematopoietic Cell Transplantation For Follicular Lymphoma: A Phase Two Multicenter Trial From The Blood And Marrow Transplant Clinical Trials Networ”. Biol Blood Marrow Transplant 22 (8). Biol Blood Marrow Transplant: 1440-1448. doi:10.1016/j.bbmt.2016.04.014.
. 2016. “Severity, Course, And Predictors Of Sleep Disruption Following Hematopoietic Cell Transplantation: A Secondary Data Analysis From The Bmt Ctn 0902 Trial.”. Bone Marrow Transplant 53 (8). Bone Marrow Transplant: 1038-1043. doi:10.1038/s41409-018-0138-0.
. 2018. “Tacrolimus/sirolimus Vs Tacrolimus/methotrexate As Gvhd Prophylaxis After Matched, Related Donor Allogeneic Hct.”. Blood 124 (8). Blood: 1372-7. doi:10.1182/blood-2014-04-567164.
. 2014. “Three Prophylaxis Regimens (Tacrolimus, Mycophenolate Mofetil, And Cyclophosphamide; Tacrolimus, Methotrexate, And Bortezomib; Or Tacrolimus, Methotrexate, And Maraviroc) Versus Tacrolimus And Methotrexate For Prevention Of Graft-Versus-Host Disease With”. Lancet Haematol 6 (3). Lancet Haematol: e132-e143. doi:10.1016/S2352-3026(18)30221-7.
. 2019. “A Trial Of Unrelated Donor Marrow Transplantation For Children With Severe Sickle Cell Disease.”. Blood 128 (21). Blood: 2561-2567. doi:10.1182/blood-2016-05-715870.
. 2016.